サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：強迫性障害治療薬の世界市場：現状分析と予測（2022年～2028年）
市場調査レポート
商品コード
1145458

強迫性障害治療薬の世界市場：現状分析と予測（2022年～2028年）

Obsessive-Compulsive Disorder Drugs Market: Current Analysis and Forecast (2022-2028)
出版日: | 発行: UnivDatos Market Insights Pvt Ltd | ページ情報: 英文 142 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
強迫性障害治療薬の世界市場：現状分析と予測（2022年～2028年）
出版日: 2022年10月01日
発行: UnivDatos Market Insights Pvt Ltd
ページ情報: 英文 142 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の強迫性障害治療薬の市場規模は、予測期間中に約7％という著しい成長率を示すと予想されています。市場の成長を後押しする主な要因には、強迫性障害の有病率の上昇、仕事上のストレスの増加、人々の間における強迫性障害の深刻さに対する認識の高まりなどが挙げられます。

当レポートでは、世界の強迫性障害治療薬市場を調査しており、市場の概要、市場規模や予測、動向、促進要因・抑制要因、薬剤タイプ別・流通チャネル別・地域別の分析、および企業プロファイルなどを提供しています。

目次

第1章 市場イントロダクション

  • 市場の定義
  • 主な目的
  • ステークホルダー
  • 制限

第2章 調査手法または前提条件

  • 強迫性障害治療薬市場の調査プロセス
  • 強迫性障害治療薬市場の調査手法
  • 回答者プロファイル

第3章 市場の要約

第4章 エグゼクティブサマリー

第5章 COVID-19の影響

第6章 強迫性障害治療薬市場の収益、2020年～2028年

第7章 市場洞察：薬剤タイプ別

  • SSRI
  • 抗不安薬
  • 抗うつ薬

第8章 市場洞察：流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第9章 市場洞察：地域別

  • 北米
    • 米国
    • カナダ
    • その他の北米
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他のアジア太平洋
  • その他の地域

第10章 強迫性障害治療薬の市場力学

  • 市場促進要因
  • 市場抑制要因
  • 影響分析

第11章 強迫性障害治療薬市場の機会

第12章 強迫性障害治療薬市場の動向

第13章 需要側と供給側の分析

  • 需要側の分析
  • 供給側の分析

第14章 バリューチェーン分析

第15章 競合シナリオ

  • 競合情勢
    • ポーターのファイブフォース分析

第16章 企業プロファイル

  • Abbott Laboratories
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Sanofi S.A.
  • Novartis AG
  • AbbVie Inc.
  • Eli Lilly and Company
  • AstraZeneca plc
  • Meiji Holdings Co. Ltd.
  • Brainsway Ltd.

第17章 免責事項

目次
Product Code: UMHE211228

The global obsessive-compulsive disorder drugs market is expected to grow at a significant rate of around 7% during the forecast period. OCD is a long-lasting mental health condition characterized by frequent thoughts or urges and repetitive behaviors or actions that people feel like they continue doing repeatedly. The rising prevalence of obsessive-compulsive disorder and increasing work-related stress are important factors that are responsible for the market growth of OCD drugs. For instance, as per the NIMH, OCD affects 2.5 million adults, or 1.2% of the U.S. population. Furthermore, the rising awareness about the severity of the disease among the population also catalyzes the market dynamics of their OCD drugs.

Abbott, Pfizer Inc., Merck & Co. Inc., Sanofi, Novartis AG, AbbVie Inc., Eli Lilly and Company, AstraZeneca, Meiji Holdings Co., Ltd, Brainsway are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst drug type, antidepressant category to witness higher CAGR during the forecast period"

Based on the drug type, the market has been categorized into SSRIs, anxiolytic, and antidepressants. The antidepressants category is to witness higher CAGR during the forecast period owing to rapidly increasing cases of mental disorders which were further increased by the lockdowns imposed during the COVID-19 pandemic. For instance, according to the WHO, the burden of mental health problems in India is 2,443 disability-adjusted life years (DALYs) per 10,000 population.

"Amongst distribution channel, the online pharmacies to hold a significant share in the market in 2020"

Based on the distribution channel, the market has been categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others. Among these, online pharmacies to hold a significant share in the market in 2020. The rising number of quick commerce platforms and increasing investment in online pharmacies are the important factors that are responsible for the segmental growth in the obsessive-compulsive disorder drugs market.

"North America to hold a significant share in the market"

For a better understanding of the market adoption of the obsessive-compulsive disorder drugs industry, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. In 2020, North America held a significant share of the global obsessive-compulsive disorder drugs market. This is mainly attributed to the rising number of product launches and the increasing healthcare investments in the region. For instance, in August 2021, Drug firm Alembic Pharmaceuticals received final approval from the US health regulator for Clomipramine Hydrochloride capsules, used for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD).

Reasons to buy this report:

  • The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
  • The report presents a quick review of overall industry performance at one glance.
  • The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.
  • Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
  • The study comprehensively covers the market across different segments.
  • Deep dive regional level analysis of the industry.

Customization Options:

The global obsessive-compulsive disorder drugs market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the obsessive-compulsive disorder drugs Market
  • 2.2. Research Methodology of the obsessive-compulsive disorder drugs Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET

6 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY DRUG TYPE

  • 7.1. SSRIs
  • 7.2. Anxiolytic
  • 7.3. Antidepressants

8 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

  • 8.1. Hospital Pharmacies
  • 8.2. Retail Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Others

9 MARKET INSIGHTS BY REGION

  • 9.1. North America
    • 9.1.1. The United States
    • 9.1.2. Canada
    • 9.1.3. Rest of North America
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. The United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Rest of Asia-Pacific
  • 9.4. Rest of World

10 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET DYNAMICS

  • 10.1. Market Drivers
  • 10.2. Market Challenges
  • 10.3. Impact Analysis

11 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET OPPORTUNITIES

12 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET TRENDS

13 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 13.1. Demand Side Analysis
  • 13.2. Supply Side Analysis

14 VALUE CHAIN ANALYSIS

15 COMPETITIVE SCENARIO

  • 15.1. Competitive Landscape
    • 15.1.1. Porters Fiver Forces Analysis

16 COMPANY PROFILED

  • 16.1. Abbott Laboratories
  • 16.2. Pfizer Inc.
  • 16.3. Merck & Co. Inc.
  • 16.4. Sanofi S.A.
  • 16.5. Novartis AG
  • 16.6. AbbVie Inc.
  • 16.7. Eli Lilly and Company
  • 16.8. AstraZeneca plc
  • 16.9. Meiji Holdings Co. Ltd.
  • 16.10. Brainsway Ltd.

17 DISCLAIMER